The global heparin market size was estimated at USD 6.49 billion in 2018and is projected to expand at a CAGR of 1.6%. Increasing number of accidents and surgeries is expected to be a key driver for the growth. Increasing incidence of venous thromboembolism and cardiovascular disorders is expected to fuel the market growth over the forecast period.
According to the data published in the Centers for Disease Control and Prevention (CDC) in 2018, around 900,000 people in U.S. are affected by deep vein thrombosis and pulmonary embolism each year. This factor is projected to propel the regional demand in the forthcoming years.
Some biopharmaceutical companies are financing resources for the development of new drugs. Organizations such as the CDC and the National Institutes of Health (NIH) are undertaking initiatives for increasing awareness levels through programs that aim preventing thrombosis-associated complications in initial stages.
High demand for anticoagulants is anticipated to boost the overall heparin market. Furthermore, high healthcare expenditures and patient awareness levels are some of the key factors anticipated to accelerate the market over the forecast period.
Based on type, the market is segmented into low molecular weight, ultra-low molecular weight, and unfractionated heparin. Low molecular weight segment held the largest heparin market share in 2018 owing to more predictable anticoagulant effect of the product.
In addition, according to a study published in NEJM Journal Watch, low incidence of heparin induced thrombocytopenia contribute towards the segment growth. Ultra-low molecular weight heparin is expected to be the fastest growing segment over the forecast period owing to commercialization of products with improved pharmacological effects.
On the basis of route of administration, the market is bifurcated into intravenous and subcutaneous. The subcutaneous segment led the market in 2018 and is expected to be the fastest growing segment with a lucrative CAGR over the coming years due to less cost associated with hospitalization.
Furthermore, on the basis of patient’s perspective, subcutaneous route is more preferred owing to ease of administration, rising preference for home care and reduced duration of treatment. Moreover, the associated benefits of this route of administration includes low risk of systemic infection and improved quality of life.
Based on the application, the market has been categorized into venous thromboembolism, atrial fibrillation, renal impairment, and coronary artery disease. Among these, coronary artery disease held the largest share in 2018 owing to increasing prevalence and incidence of heart-related disorders.
According to statistics published in the American Heart Association, in 2018, around 92.1 million American adults were suffering from some form of cardiovascular disease. In addition, around 1 in every 3 deaths are caused by cardiovascular disease in the U.S. accounting for around 2,300 deaths per day.
Venous thromboembolism (VTE) is expected to be the fastest growing segment over the forecast period. Venous thromboembolism is segmented into pulmonary embolism (PE) and deep vein thrombosis (DVT). Increasing awareness of thrombosis is one of the major factors driving the segment growth. For instance, introduction of online portal by International Society on Thrombosis and Haemostasis, Inc. is expected to improve the awareness of thrombosis amongst patients.
Moreover, increasing mortality rates of venous thromboembolism is anticipated to contribute towards the segment growth. According to the facts published in the International Society on Thrombosis and Haemostasis, Inc., around 10 million cases of VTE is recorded globally every year and around 544,000 VTE related deaths are observed every year in Europe.
On the basis of end use, the market is segmented into inpatients and outpatients. Outpatient was the largest segment in 2018 and is estimated to witness the fastest CAGR of 2.4% over the forecast period. Increasing preference of subcutaneous route of administration among the patients is a major factor responsible for market growth.
In addition, outpatient hospital cost is less as compared inpatient hospital cost. Moreover, according to various studies published in the NCBI, outpatient therapy was associated with lower rate of recurrent venous thromboembolism.
In 2018, North America led the overall market in terms of revenue owing to the increasing sports injury and cardiovascular disorders. Furthermore, higher healthcare expenditure levels, high patient awareness, and sophisticated healthcare infrastructure in this region are the factors that can be attributed to the region’s high share.
According to the American Physical Therapy Association, the average annual injury is around 8.6 million every year accounting for an age-adjusted rate of 34.1 per 1000 population. It was also stated that around 65% of the injuries were caused among individuals aged 5-24 years.
Asia Pacific is anticipated to witness the fastest growth in the forthcoming years. Constantly improving healthcare infrastructure, presence of untapped opportunities, economic development, and rising initiatives by private and public organizations are some factors that can be accredited to the rapid growth of the region.
The key players are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd.
Mostly, the companies are involved in implementing strategies such as mergers and acquisitions, collaborations, and product development to increase their market share. For instance, in 2018, Fresenius Kabi launched heparin sodium in ready-to-administer non DEHP freeflex bags, thus expanding the company’s critical care portfolio.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2018 to 2026
North America, Europe, Asia Pacific, Latin America, MEA
Revenue forecast, company share, competitive landscape, growth factors, and trends
U.S., Canada, U.K., Germany, France, Italy, Spain, Russia, Mexico, Brazil, Argentina, Japan, China, India, South Korea, Australia, Singapore, South Africa, UAE, Saudi Arabia
15% free customization scope (equivalent to 5-analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2026. For the purpose of this study, Grand View Research has segmented the global heparin market report on the basis of type, route of administration, application, end use, and region:
Type Outlook (Revenue, USD Million, 2014 - 2026)
Low Molecular Weight Heparin
Ultra-low Molecular Weight Heparin
Route of Administration Outlook (Revenue, USD Million, 2014 - 2026)
Application Outlook (Revenue, USD Million, 2014 - 2026)
Coronary Artery Disease
End Use Outlook (Revenue, USD Million, 2014 - 2026)
Regional Outlook (Revenue, USD Million, 2014 - 2026)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."